News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Proteome Sciences PLC H1 Pretax Loss Narrows; Sees Licensing for TMT by Year-End
October 2, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Proteome Sciences PLC posted a narrower first half pretax loss and higher revenues and said it is "well set" to provide strong and sustainable revenue stream.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
July 20, 2026
·
3 min read
·
Heather McKenzie
IPO
2026 IPO class blooms again as BlossomHill, Latigo set sights on Nasdaq
July 20, 2026
·
2 min read
·
Tristan Manalac
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 17, 2026
·
1 min read
·
Gabrielle Masson
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
July 17, 2026
·
1 min read
·
Tristan Manalac
